Prof Brian Van Tine speaks to ecancer in an online interview for the virtual ASCO 2021 meeting about the SPEARHEAD-1 trial.
This was a phase II trial of afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.advanced synovial sarcoma.
He reports that the use of afamitresgene autoleucel showed durable, prolonged responses with toxicities in safe levels.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.